A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Registration Number
- NCT05306340
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 320
-
Locally advanced unresectable or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
-
Documented estrogen receptor-positive (ER+) tumor and HER2-negative tumor, assessed locally
-
Ability to provide a blood sample for circulating-tumor deoxyribonucleic acid (ctDNA) Estrogen Receptor 1 (ESR1) mutation status determination by central testing
-
Prior endocrine therapy (ET) in combination with cyclin-dependent kinase 4/6 inhibitors in either setting as follows:
- Metastatic setting: Disease progression after ≥6 months on ET plus CDK4/6 inhibitor in the locally advanced or metastatic setting. If ET plus CDK4/6 inhibitor is not the most recent therapy, then patient must also have had disease progression after ≥4 months on most recent ET
- Adjuvant Setting: Relapse either while taking or within 12 months of exposure to combination adjuvant ET and CDK4/6 inhibitor. Patients must have taken at least 12 months of adjuvant ET, 6 months of which was in combination with a CDK4/6 inhibitor.
-
Measurable disease as defined per RECIST v.1.1 or evaluable bone metastases. Patients with evaluable bone disease in the absence of measurable disease outside of the bone must have at least one predominantly lytic bone lesion confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) which can be followed
-
Eastern Cooperative Oncology Group Performance Status 0-1
-
For women who are premenopausal or perimenopausal and for men: treatment with approved luteinizing hormone-releasing hormone (LHRH) agonist therapy for the duration of study treatment
- Prior treatment with another oral selective estrogen receptor degrader (SERD), proteolysis targeting chimera (PROTAC), complete estrogen receptor antagonist (CERAN), novel oral selective estrogen receptor modulator (SERM), or everolimus in any setting. Prior fulvestrant is allowed if treatment was terminated at least 28 days prior to randomization. Prior treatment with tamoxifen is allowed.
- Progression on more than 2 prior lines of systemic endocrine therapy in the locally advanced unresectable or metastatic breast cancer setting
- Prior chemotherapy for locally advanced unresectable or metastatic disease
- Treatment with strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
- Treatment with any investigational therapy within 28 days prior to initiation of study treatment
- Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days prior to randomization
- History of any other malignancy other than breast cancer within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, papillary thyroid cancer treated with surgery, Stage I endometrial cancer, or other non-breast cancers at very low risk of recurrence
- Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease
- Active cardiac disease or history of cardiac dysfunction
- Known clinically significant history of liver disease consistent with Child-Pugh Class B or C including active viral or other hepatitis virus, current alcohol abuse, or cirrhosis
- Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery including gastric resection
- Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy
- Serious infection requiring oral or intravenous (IV) antibiotics, or other clinically significant infection, within 14 days prior to randomization
- Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
- Known allergy or hypersensitivity to any of the study drugs or any of their excipients
- For premenopausal or perimenopausal women and for men: known hypersensitivity to LHRH agonists
- Pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Giredestrant plus Everolimus Giredestrant - Giredestrant plus Everolimus LHRH Agonist - Giredestrant plus Everolimus Dexamethasone Mouth Rinse - Physician's Choice of Endocrine Therapy plus Everolimus Fulvestrant The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen. Physician's Choice of Endocrine Therapy plus Everolimus Dexamethasone Mouth Rinse The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen. Physician's Choice of Endocrine Therapy plus Everolimus Tamoxifen The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen. Physician's Choice of Endocrine Therapy plus Everolimus LHRH Agonist The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen. Giredestrant plus Everolimus Everolimus - Physician's Choice of Endocrine Therapy plus Everolimus Exemestane The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen. Physician's Choice of Endocrine Therapy plus Everolimus Everolimus The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen.
- Primary Outcome Measures
Name Time Method Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months) The Intent-to-Treat (ITT) population consists of all randomized participants, and the ESR1m subpopulation is defined as participants in the ITT population whose tumors harbor a detectable Estrogen Receptor 1 (ESR1) mutation at baseline as measured in circulating tumor DNA (ctDNA).
- Secondary Outcome Measures
Name Time Method Overall Survival, in the ESR1m Subpopulation and ITT Population From randomization until death from any cause (up to 42 months) Time to Confirmed Deterioration in Health-Related Quality of Life (HRQoL), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Global Health Status (GHS)/QoL Scale Score, in the ESR1m Subpopulation and ITT Population From randomization until 90 days after treatment discontinuation (up to 42 months) Time to confirmed deterioration in HRQoL is defined as the time from randomization to the first documentation of ≥10-point decrease in GHS/QoL score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30
Objective Response Rate (ORR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population From randomization until progressive disease or death (up to 42 months) The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart.
Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 42 months) Time to Confirmed Deterioration in Physical Functioning (PF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed PF Scale Score, in the ESR1m Subpopulation and ITT Population From randomization until 90 days after treatment discontinuation (up to 42 months) Time to confirmed deterioration in physical functioning (PF) is defined as the time from randomization to the first documentation of ≥10-point decrease in PF score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30
Time to Confirmed Deterioration in Pain Presence and Interference, as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Pain Scale Score, in the ESR1m Subpopulation and ITT Population From randomization until 90 days after treatment discontinuation (up to 42 months) Time to confirmed deterioration in pain presence and interference is defined as the time from randomization to the first documentation of ≥10-point increase in pain score held for 2 consecutive time points, or a ≥10-point increase followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30
Clinical Benefit Rate (CBR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population From Baseline until progressive disease or death (up to 42 months) The clinical benefit rate is defined as the percentage of participants with stable disease for at least (≥)24 weeks or a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart.
Time to Confirmed Deterioration in Pain Severity, as Determined Using the Brief Pain Inventory Short-Form (BPI-SF) Worst Pain Item Score, in the ESR1m Subpopulation and ITT Population From randomization until 90 days after treatment discontinuation (up to 42 months) Time to confirmed deterioration in pain severity is defined as the time from randomization to the first documentation of ≥2-point increase from baseline on the "worst pain" item score (scale from 0 = "No pain" to 10 = "Pain as bad as you can imagine") held for 2 consecutive time points, or a ≥2-point increase followed by death attributable to cancer progression within 28 days from the last assessment.
Time to Confirmed Deterioration in Role Functioning (RF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed RF Scale Score, in the ESR1m Subpopulation and ITT Population From randomization until 90 days after treatment discontinuation (up to 42 months) Time to confirmed deterioration in role functioning (RF) is defined as the time from randomization to the first documentation of ≥10-point decrease in RF score held for 2 consecutive time points, or a ≥10-point decrease followed by death attributable to cancer progression within 28 days from the last assessment. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life-Core 30
Number of Participants with at Least One Adverse Event, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0) From Baseline until 30 days after the final dose of study treatment (up to 42 months) Number of Participants with Vital Sign Abnormalities Over the Course of the Study From Baseline until 30 days after the final dose of study treatment (up to 42 months) Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure while the patient is in a seated position, and temperature.
Number of Participants with Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study From Baseline until 30 days after the final dose of study treatment (up to 42 months) Number of Participants with Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study From Baseline until 30 days after the final dose of study treatment (up to 42 months) Plasma Concentration of Giredestrant at Specified Timepoints Predose and 3 hours postdose on Days 1 and 15 of Cycle 1, and predose on Day 1 of Cycles 2 and 3 (1 cycle is 28 days)
Trial Locations
- Locations (178)
Nagoya University Hospital
🇯🇵Aichi, Japan
Medical Oncology Centre of Rosebank
🇿🇦Johannesburg, South Africa
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
🇪🇸La Coruña, LA Coruna, Spain
Hospital Dexeus
🇪🇸Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
C.H. Regional Reina Sofia - PPDS
🇪🇸Cordoba, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Instituto de Oncologia de Rosario
🇦🇷Rosario, Argentina
Alabama Oncology - Bruno Cancer Center
🇺🇸Birmingham, Alabama, United States
Alaska Oncology and Hematology
🇺🇸Anchorage, Alaska, United States
The Dignity Health Cancer Institute
🇺🇸Phoenix, Arizona, United States
Arizona Oncology Associates, PC-CASA
🇺🇸Tucson, Arizona, United States
Genesis Cancer Center
🇺🇸Hot Springs, Arkansas, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Pacific Cancer Medical Center
🇺🇸Anaheim, California, United States
Alta Bates Summit Medical Center
🇺🇸Berkeley, California, United States
Beverly Hills Cancer Center
🇺🇸Beverly Hills, California, United States
TOI Clinical Research
🇺🇸Cerritos, California, United States
Newport Beach UC Irvine Medical Center
🇺🇸Costa Mesa, California, United States
Women's Cancer Care
🇺🇸Fresno, California, United States
Scripps Health
🇺🇸La Jolla, California, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
University of California, Irvine Medical Center
🇺🇸Orange, California, United States
Emad Ibrahim, Md, Inc
🇺🇸Redlands, California, United States
Brian LeBerthon, Med Corp
🇺🇸West Covina, California, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Eastern CT Hematology and Oncology Associates
🇺🇸Norwich, Connecticut, United States
ASCLEPES Research Centers - Brooksville
🇺🇸Brooksville, Florida, United States
Broward Health Medical Center (BHMC) (Broward General Medical Center (BGMC))
🇺🇸Fort Lauderdale, Florida, United States
Mount Sinai Medical Center
🇺🇸Miami Beach, Florida, United States
Orlando Health Cancer Institute
🇺🇸Orlando, Florida, United States
Cancer Care Centers of Brevard
🇺🇸Rockledge, Florida, United States
Tampa General Hospital Cancer Institute
🇺🇸Tampa, Florida, United States
Northern Light Cancer Center/Oncology Research
🇺🇸Brewer, Maine, United States
Florida Cancer Specialists
🇺🇸West Palm Beach, Florida, United States
Northwest Georgia Oncology Centers PC - Marietta
🇺🇸Marietta, Georgia, United States
Summit Cancer Care PC
🇺🇸Savannah, Georgia, United States
St Luke?s Cancer Institute
🇺🇸Meridian, Idaho, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
OSF Little Company of Mary Hospital
🇺🇸Evergreen Park, Illinois, United States
Duly Health and Care
🇺🇸Joliet, Illinois, United States
Springfield Clinic
🇺🇸Springfield, Illinois, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
Mission Cancer + Blood - IMMC
🇺🇸Des Moines, Iowa, United States
University of Kansas Cancer Center
🇺🇸Westwood, Kansas, United States
Pikeville Medical Center
🇺🇸Pikeville, Kentucky, United States
Our Lady of the Lake Physicians Group
🇺🇸Baton Rouge, Louisiana, United States
Woman's Hospital
🇺🇸Baton Rouge, Louisiana, United States
Pontchartrain Cancer Center
🇺🇸Covington, Louisiana, United States
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
Anne Arundel Health System Research Institute
🇺🇸Annapolis, Maryland, United States
University of Maryland Greenebaum Cancer Center
🇺🇸Baltimore, Maryland, United States
Mercy Medical Center
🇺🇸Baltimore, Maryland, United States
TidalHealth Peninsula Regional; Richard A. Henson Research
🇺🇸Ocean Pines, Maryland, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Dana Farber/Harvard Cancer Center (Foxborough)
🇺🇸Foxboro, Massachusetts, United States
Dana Farber/Harvard Cancer Center (Milford)
🇺🇸Milford, Massachusetts, United States
Dana Farber/Harvard Cancer Center (Weymouth)
🇺🇸Weymouth, Massachusetts, United States
Metro-Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
Oncology Hematology West PC
🇺🇸Grand Island, Nebraska, United States
Nebraska Cancer Specialists
🇺🇸Omaha, Nebraska, United States
Renown Regional Medical Center
🇺🇸Reno, Nevada, United States
Memorial Sloan Kettering - Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Summit Medical Group
🇺🇸Florham Park, New Jersey, United States
Memorial Sloan Kettering - Monmouth
🇺🇸Middletown, New Jersey, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
San Juan Oncology Associates
🇺🇸Farmington, New Mexico, United States
Memorial Sloan Kettering
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Cancer Center at Westchester
🇺🇸Harrison, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸Long Island City, New York, United States
The Blavatnik Family ? Chelsea Medical Center at Mount Sinai
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Stony Brook University Medical Center
🇺🇸Stony Brook, New York, United States
Memorial Sloan Kettering Cancer Center at Nassau
🇺🇸Uniondale, New York, United States
SCRI Mark H. Zangmeister Center
🇺🇸Columbus, Ohio, United States
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute
🇺🇸Tulsa, Oklahoma, United States
St Charles Medical Center Bend
🇺🇸Bend, Oregon, United States
Abramson Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center - Magee-Women?s Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Abramson Cancer Center Chester County Hospital
🇺🇸West Chester, Pennsylvania, United States
McGlinn Cancer Institute at Reading Hospital
🇺🇸West Reading, Pennsylvania, United States
Avera Cancer Institute
🇺🇸Sioux Falls, South Dakota, United States
West Cancer Center
🇺🇸Germantown, Tennessee, United States
Thompson Cancer Survival Center
🇺🇸Knoxville, Tennessee, United States
Texas Oncology P.A - Beaumont
🇺🇸Beaumont, Texas, United States
Texas Oncology
🇺🇸Bedford, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Texas Oncology-Denton South
🇺🇸Denton, Texas, United States
Texas Oncology, P.A. - El Paso
🇺🇸El Paso, Texas, United States
Houston Methodist Cancer Center
🇺🇸Houston, Texas, United States
Millennium Research & Clinical Development
🇺🇸Houston, Texas, United States
USOR - Texas Oncology - San Antonio Northeast
🇺🇸San Antonio, Texas, United States
Inova Fairfax Hospital
🇺🇸Fairfax, Virginia, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Instituto de Oncología Ángel H. Roffo
🇦🇷Agronomía, Ciudad Autónoma De BuenosAires, Argentina
Fundación CENIT para la Investigación en Neurociencias
🇦🇷Recoleta, Ciudad Autónoma De BuenosAires, Argentina
Consultorios Médicos Dr. Doreski
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Centro Medico Privado CEMAIC
🇦🇷Cordoba, Argentina
Fundacion Centro Oncologico de Integracion Regional (COIR)
🇦🇷Mendoza, Argentina
Instituto Medico de la Fundacion Estudios Clinicos
🇦🇷Rosario, Argentina
Sanatorio Parque S.A.
🇦🇷Rosario, Argentina
Hospital Provincial del Centenario
🇦🇷Rosario, Argentina
Centro Polivalente de Asistencia e Investigacion Clinica - CER San Juan
🇦🇷San Juan, Argentina
Organizacion Medica de Investigacion
🇦🇷San Nicolás, Argentina
Centro de Investigación Clínica ? Clínica Viedma
🇦🇷Viedma, Argentina
Marienhospital Bottrop
🇩🇪Bottrop, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
Kliniken Essen-Mitte
🇩🇪Essen, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
🇩🇪Mainz, Germany
Universitatsklinikum Munster
🇩🇪Münster, Germany
University of Athens, Hematological Clinic,
🇬🇷Athens, Greece
Attikon University General Hospital
🇬🇷Athens, Greece
Metropolitan General Hospital
🇬🇷Cholargos, Greece
University General Hospital of Heraklion
🇬🇷Heraklio, Greece
University General Hospital of Larissa
🇬🇷Larissa, Greece
IASO Obstetrics Gynecology Clinic
🇬🇷Marousi, Greece
Agios Loucas Clinic SA
🇬🇷Panorama, Greece
Olympion Clinic
🇬🇷Patras, Greece
University General Hospital of Patras
🇬🇷Patras, Greece
Metaxa Cancer Hospital of Piraeus
🇬🇷Peiraias, Greece
Interbalkan Medical Center of Thessaloniki
🇬🇷Thessaloniki, Greece
Euromedica PPDS
🇬🇷Thessaloniki, Greece
Azienda Ospedaliero - Universitaria di Modena Policlinico
🇮🇹Modena, Emilia-Romagna, Italy
Istituto Nazionale Tumori Regina Elena IRCCS
🇮🇹Roma, Lazio, Italy
Ospedale Policlinico San Martino
🇮🇹Genova, Liguria, Italy
Asst Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Lombardia, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti
🇮🇹Torrette Di Ancona, Marche, Italy
"Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"
🇮🇹Verona, Veneto, Italy
Aichi Cancer Center
🇯🇵Aichi, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
National Cancer Center Hospital East
🇯🇵Chiba, Japan
Shikoku Cancer Center
🇯🇵Ehime, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
Hokkaido University Hospital
🇯🇵Hokkaido, Japan
Hyogo Cancer Center
🇯🇵Hyogo, Japan
University of Tsukuba Hospital
🇯🇵Ibaraki, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Tokai University Hospital
🇯🇵Kanagawa, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Juntendo University Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Soon Chun Hyang University Cheonan Hospital
🇰🇷Dongnam-gu, Cheonan-si, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System - PPDS
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
National University Hospital
🇸🇬Singapore, Singapore
Oncocare Cancer Centre
🇸🇬Singapore, Singapore
Rainbow Oncology Private Practice
🇿🇦Amanzimtoti, South Africa
Hopelands Cancer Centre
🇿🇦Hilton, South Africa
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital General Universitario J.M Morales Meseguer
🇪🇸Murcia, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Changhua Christian Hospital
🇨🇳Chang Hua, Taiwan
Chang Gung Memorial Hospital
🇨🇳Kaohsiung Country, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital - Linkou Branch
🇨🇳Taipei, Taiwan
Memorial Ankara Hastanesi
🇹🇷Ankara, Turkey
SAKARYA University Medical Faculty
🇹🇷Sakarya, Turkey
Dorset County Hospital
🇬🇧Dorchester, United Kingdom
North Middlesex Uni Hospital
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom